CATALINA
Dec 01 2020
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (CATALINA) Sponsor: NGM Biopharmaceuticals, Inc.…
Read MoreDERBY/GALE
Jun 12 2019
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (DERBY)…
Read MoreOAKS/GALE
Jun 12 2019
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS)…
Read MoreARIS
Jan 28 2019
Age-Related Macular Degeneration Ryan Initiative Study (ARIS) Sponsor: National Eye Institute Principal Investigator: Barbara Blodi, MD Study coordinator: Kris Dietzman Study objective: To understand the progression of age-related macular degeneration from early to late-stage disease…
Read More